Immunocore Presents Ovarian Cancer Expansion Data For ImmTAC Candidate IMC-C103C Targeting MAGE-A4

Immunocore Holdings PLC IMCR:

• IMMUNOCORE PRESENTS OVARIAN CANCER EXPANSION DATA FOR IMMTAC® CANDIDATE IMC-C103C TARGETING MAGE-A4

• IMMUNOCORE HOLDINGS PLC- IMC-C103C HAS MANAGEABLE SAFETY PROFILE AND DEMONSTRATED SIGNALS OF CLINICAL ACTIVITY

• IMMUNOCORE HOLDINGS PLC - PHASE 1 TRIAL ENROLLED ALL COMERS, WITH VAST MAJORITY OF PATIENTS HAVING ZERO OR VERY LOW MAGE-A4 EXPRESSION

• IMMUNOCORE HOLDINGS PLC - RECIST RESPONSE RATE WAS LOW IN POPULATION WITH ZERO OR VERY LOW MAGE-A4 EXPRESSION